You are on page 1of 1

LD score, to be admitted for hepatic encephalopathy, to stay in the intensive care unit, and to undergo invasive procedure.

Logistic regression identified admission for hepatic encephalopathy [odds ratio (OR) = 2.301, 95% confidence interval (CI) = 1.7–9.8], high MELD score (OR = 2.337, 95% CI = 1.03–1.22) and corticosteroid treatment as

Portal vein thrombosis in liver cirrhosis
Irina Girleanu, Anca Trifan, Oana Cristina Stoica, Camelia Cojocariu, Ana Maria Singeap, Stefan Chiriac, Tudor Cuciureanu, Catalin Sfarti, Carol
Stanciu
“Gr. T. Popa” University of Medicine and Pharmacy
Institute of Gastroenterology and Hepatology, Iasi

Background: Portal vein thrombosis (PVT), a common complication in the patients with cirrhosis, is
often neglected and influenced on clinical manifestation and prognosis for cirrhosis patients. Aim: To
investigate the clinical characteristics and natural course of portal vein thrombosis (PVT) in patients
with cirrhosis.

Methodology: In this study we included 65 cirrhotic patients with PVT as study group and 70 without
PVT as control group admitted in our hospital between January 1 st 2013 to December 31, 2014.
General information, laboratory results, imaging findings, clinical manifestations and complications
were recorded and analyzed. Clinical characteristics were compared, and corresponding risk factors
were selected. All the patients were follow-up until December 31, 2016.

Results: There were no difference regarding baseline Results: During follow up portal vein thrombosis
characteristics between the two study group. improved in 11 patients (16.9%), was stable in 36
(55.3%), and worsened in 18 (27.7%). Hepatic
decompensation rate at 6 and 18 months was higher
in patients with worsened PVT than in those with
stable/improved PVT and control group. The survival
rate at 6 months was the same in all the study groups.
Parameter PVT Control group p
(n=65) (n=70)

Age, yrs, mean±SD, 58,9±12,1 56±11,8 0,797

Sex, M/F, n 35/30 32/38 0.886

Score MELD, mean±SD 21,4±9 15,5±10 <0,001

Child-Pugh A(%) 0 2.8 0.986

B(%) 24.6 21.5

C(%) 75.4 75.7

Albumine (mg/dl), mean±SD 2,9±0,6 3,8±0,7 0,014

INR, mean±SD 1,65±0,4 1,43±0,3 0,232

aPTT (s), mean±SD 24±5 23±4 0,655

Prothrombin activity (%), 58±13 65±13 0,078
mean±SD

Fibrinogen (mg/dl), 175±20,7 230±16,9 0,068
mean±SD
Platelets (/mmc), mean±SD 97.268±1253 118.025±24.33 0,057
4 8

Risk factors for decompensation in patients with PVT and liver cirrhosis
With progression Without p
n=18 progression
n=47
Parameter Univariate analysis
MELD score 14.83±2.99 14.12±2.60 0.806
Child score 9±0.89 9.2±1.64 0.816 OR IC 95% p
Albumine (mg/dl) 4.34±10.99 5.07±10.36 0.348
Prothrombin time (sec) 19,62±3.87 18.62±7.06 0.795
Hypoalbuminemia 1.39 0.90-5.09 0.087

Presentation 10/8 27/20 0.852 Score MELD 2.52 1.28-6.99 0.032
(asympt/sympt)
Age (years) 58.17±4.79 63.20±4,86 0.121
Spontaneous bacterial 1.50 0.85-5.23 0.129
aPTT 56.75±24.67 62±26.05 0.769
peritonitis
Platelets (/mmc) 122333±60437 125600±71632 0.941

Results: Multivariate analysis showed that Model of End‑Life Disease was the independent predictor of hepatic
decompensation [hazard ratio (HR) 2.52; 95% confidence interval (CI): 1.28–6.99, P = 0.032] and survival (HR 4.76; 95% CI:
2.06–6.92, P = 0.027)

Conclusions: Nonmalignant partial PVT remained stable/improved in over half of cirrhotic patients and aggravated in
more than one fourth in whom it negatively influenced the decompensation rates with no influence on survival.